Sunday, September 22, 2013

Badgers football: Ohio State rivalry takes on added intrigue

University of Wisconsin senior nose guard Beau Allen can be forgiven for not being up to speed on all of the forthcoming changes in the Big Ten Conference.

After all, Allen will be gone - almost certainly playing in the NFL - when the Big Ten unveils the East and West divisions, starting in 2014 with the additions of Rutgers and Maryland, with a nine-game conference schedule to follow in 2016.

"This might be bad to admit, but I don't know what's going on with the (divisions) and the Big Ten," Allen said after the Badgers' 41-10 victory over Purdue on Saturday.

The first thing Allen needs to learn is the boiling rivalry with Ohio State is about to be reduced to a simmer.

Starting next season, when UW is in the West and Ohio State is in the East, the Buckeyes will no longer be Public Enemy No. 1 when it comes to the Badgers. UW will be more focused on division foes Northwestern, Iowa and Nebraska than it will be on Ohio State.

That makes an already intriguing matchup on Saturday in Columbus, Ohio, between No. 23 UW (3-1, 1-0 Big Ten) and No. 4 Ohio State (4-0, 0-0) even more enticing.

It's the end of bitterly contested era for the two teams - who won't play each other again in the regular season until 2016 - but in some ways, the changes have already started. Ohio State coach Urban Meyer and UW coach Gary Andersen are close friends who have the utmost respect for each other, which has to leave both fan bases feeling a bit uneasy.

It was easier the previous seven years, when Bret Bielema was the Badgers' coach and he seemed obsessed about everything Scarlet and Gray.

That didn't help Bielema's record against Ohio State (1-5), the only victory coming by a 31-18 margin at Camp Randall Stadium against the nation's top-ranked team in 2010.

Still, the Badgers can boast of winning the past three Big Ten titles, helped by Ohio State's ineligibility for the postseason last year. The Buckeyes won five straight titles from 2005 to 2009, vacating their share of the regular-season title in 2010 due to NCAA sanctions.

Now comes one final meeting as division rivals in what is shaping up to be the most-anticipated game in the Big Ten this season.

"It will be a high-energy game," UW sophomore tailback Melvin Gordon said. "I know Ohio State has a thing for us and we have a thing for them. We have been back and forth and those guys are playing at a high level right now, so it will be a tough game.

"But we will compete with them. Playing on the road is hard, it's not easy to win on the road. With the freshmen being able to play their first road game (at Arizona State), we have some experience. We are ready."

Ohio State backup quarterback Kenny Guiton was certainly ready, making his second straight start in place of injured starter Braxton Miller on Saturday. Guiton threw a school-record six touchdown passes, all of them in the first half in a 76-0 rout of Florida A&M.

Guiton has 13 touchdown passes on the season, including 10 in the past two games. He has thrown for 664 yards, including 491 in the past two games.

Miller suffered an MCL sprain in his right knee early in the win over San Diego State in the Buckeyes' second game. Meyer was hoping to get Miller back for the last game, but it didn't happen.

"I wanted to play him," Meyer said. "Braxton felt like he couldn't go. He tried really hard, we had a good week of pushing him through, but with good athletes, those (knee sprains) are tough injuries."

In case there was any doubt, Meyer said Miller remains the starter, if healthy. But Meyer also indicated Guiton has done enough to deserve a role.

"(Miller) is our starting quarterback," Meyer said. "Our backup quarterback has earned some time. I can't begin tell you how. I've been going through scenarios in my mind, and I don't know what it is. I'm going to see how we practice this week, but Braxton is our starting quarterback."

The Badgers come into the game with the nation's No. 3-ranked rushing offense, averaging 349.8 yards per game.

Gordon leads the Big Ten in rushing by nearly 40 yards per game, averaging 156. Senior James White is fourth at 110.5 and freshman Corey Clement is eighth at 83.5.

"We have a great group, offensive line, tight ends and running backs," senior left guard Ryan Groy said after the Badgers rushed for 388 yards against Purdue. "We prepare really well during the week. I don't think it's much of a surprise when we have those kind of numbers."

The Badgers have some injury concerns of their own, notably senior tight end Jacob Pedersen, who suffered a sprained MCL in his left knee against Purdue, along with center Dallas Lewallen and cornerback Peniel Jean, who both left the game with leg injuries.

Even though the Badgers suffered a heartbreaking 32-30 loss at Arizona State on Sept. 14, they believe being in a tough road environment prepared them for what they will face this week.

Andersen said he hasn't been to Ohio State since a recruiting trip in 1986.

"I know it's all changed since I was there," he said. "(I'm) excited about going in there. I know it's a great stadium.

"But the fact that we've gone on the road once and traveled is big for us. I know that's a tough place to play ... but our kids will still be prepared."

Source: Madison

Cayman's doctor on adult diseases Dr Olayinka A Adedayo has said that despite numerous technological breakthroughs in the fight against HIV, the country's government has been left to bear the healthcare cost of the infection that is indifferent to most insurance companies.

In an exclusive release to Cayman Net News ahead of his national presentation about the HIV disease, Dr Olayinka noted that government has been forced to bear most of the cost. This is so because of stigmatisation of the disease, which means that most of the information is never public.

"The average healthcare cost of HIV treatment is astronomical due to cost of drugs. The newer one tablet /day polypills needed for treatment are very cost prohibitive with one month's supply cost ranging from $1,900-$2,500," he stated.

"The once a day polypill "Atripla" now used in most good centres in medically advanced countries as the starting medication for HIV care has being in use in Cayman Islands since 2009.

"The global funding for HIV care by most foundations mostly go to underdeveloped and developing nations which excludes most Carribean states, thus leaving the burden of HIV care to government financing solely.

"With current changes in global economy and the rising cost of healthcare, the leading role of HIV control through excellent care that Cayman enjoys may also be threatened without involvement of private organisations.

The Bill Gates and Bill Clinton did a lot for HIV funding," he said in the press release.

"It's time for private organisations and industries to support Cayman AIDS foundation to achieve a shared United nations vision of zero new infection, zero discrimination and zero AIDS related death. A world without AIDS," Dr Olayinka stated.

Below is the text of his statement on HIV/AIDS: Over the last 30 years, a lot of advances in science and medicine have made significant and dramatic progress in HIV/AIDS since inception. HIV/AIDS started as a mysterious disease of obscure aetiology that resulted in definite death, public discrimination and social isolation. Today, we have made significant inroad to understand a disease that is now completely controlled and very close to a permanent cure, a rallying point of love and compassion, global demonstration of solidarity and a clear hope of a world without HIV/AIDS. HIV/AIDS was initially described in 1981 IN New York and Los Angeles when an abnormal clustering of a very rare vascular tumour called Kaposi's Sarcoma was seen in middle aged homosexual men that were mostly whites. They all had complications of other infections not normally seen in healthy people with a competent immune system such as pnemocystis pneumonia [a rare pneumonia],brain toxoplasmosis [brain parasite], cryptococcal meningitis [brain fungal infection], extensive Candida infection, incurable herpes and others. It spread like a wildfire and in a few years became a worldwide pandemic with presence in every region of the world. Today over 34 million still live with HIV/AIDS and over 35 million deaths since the description of the first case. There are about 7,000 new infections daily worldwide. The Center for Disease Control, Atlanta announced the emergence of this strange disease and called it "Acquired Immunodeficiency disease [AIDS] due to the overwhelming loss of immune ability in afflicted individuals who are subsequently prone to life threatening infections and cancers. Prior to this, it was called "GRID", gay-related immune-deficiency disease," and the "4H Disease", referring to homosexuals, haemophiliacs, Haitians and heroin users. By 1982, it was clear that though it initially occurred more in homosexuals, it also afflicted heterosexuals, new born infants, recipients of blood products and IV heroin users suggesting a transmissible infectious aetiology. The infective cause was identified in 1983/1984 through the combined efforts of scientists at the Louis Pasteur Institute in Paris and National Cancer Institute in USA. A lot of time was lost initially through back and forth on the origin of this mysterious disease, which allowed it to spread further worldwide. Out of all the theories advanced as its etiology, "the bush meat hunter theory" was the most accepted. The "bush meat hunter theory" suggests that a similar virus lived for years in Chimpanzees in Central Africa. A bush meat hunter might have being infected possibly during butchering of a chimpanzee with a variant of same virus that eventually proved very pathogenic to man, lived in man and could not be eradicated. By the year 1983, the AIDS hysteria became worldwide and there were reports of landlords in New York evicting AIDS patients from their homes. This reached a new height in 1985 when the world was shocked with the case of Ryan White, a teenage boy from Kukomo in Indiana, with haemophilia but HIV infected during transfusion. He was ejected from school because of his HIV status. Though given 6 months to live, he lived for 5 more years becoming the strongest advocate for this new challenge and became the face of HIV/AIDS in American posters. There was further attention when American celebrity and Hollywood star collapsed in an hotel in Paris on 21st July 1985 and was later declared to be having AIDS. He died in October 1985 but prior to his death he stated that, "I am not happy that I am sick. I am not happy that I have AIDS, but if that is helping others I can at least know that my own misfortune had some positive worth. William M Huffman [artist/author] stated "If Rock Hudson can have it, nice people can have it, it's just a disease." Rock Hudson died in October 1985 and after his death, Morgan Fairchild stated: "Rock Hudson's death gave AIDS a face." Other celebrities who succumbed to AIDS included Michael Bennett [American musical director], Freddie Mercury [British musician], Arthur Ashe [World Tennis No.1 player], Liberace [a former highest paid entertainer in the world],Tina Chow [model,jewelry designer,influential fashion icon] etc. The global response became massive after the death of Rock Hudson, which included the launching of the American Foundation for AIDS Research co-chaired by long time associate of Rock Hudson, Elizabeth Taylor. Former US president George Bush Jr. in the largest healthcare funding in history launched "PEPFAR" [Presidents Emergency Plan for AIDS relief] with an initial $15 billion dollars over 5 years towards prevention, diagnosis and treatment of HIV/AIDS especially in Sub-Sahara Africa. The PEPFAR project averted about 1.1 million deaths from HIV/AIDS in Africa. The other major contributors to HIV/AIDS financing were Bill and Melinda Gates foundation, former president Bill Clinton health access initiative through the Bill Clinton Foundation, which aimed at tripling the number of people receiving anti-retroviral treatment in South Africa and provides funds for large scale treatment. The Ryan White act was enacted in 1990 as a Public health service act [XXV1]-HIV/AIDS-1990. The programme makes US federal government funds available to assist in healthcare costs and support services for individuals and families affected by HIV/AIDS. The funds mostly went to low income, un-insured and under insured people. In October 2009,President Obama signed the Ryan White HIV/AIDS treatment extension act,2009. The first drug introduced for treatment in 1987 was Zidovudine [AZT] as monotherapy, but was a failure due to development of resistance after a few years though it reduced maternal to child transmission by 30 per cent. However in 1995, combination treatment with at least three different drugs were introduced, and this opened a new chapter in HIV care as death due to AIDS was reduced by as much as 25 per cent. Combination therapy resulted in undetectable virus in the blood, but a new challenge emerged, there was the problem of too many tablets, significant metabolic complications and increased cardiovascular risk. Over the years, advancement in understanding the mechanism by which HIV cause disease had led to newer drugs with less side effects, more potent, and finally the polypills with three drugs in one tablet/once a day or four drugs in one tablet/once a day. This advancement has brought significant changes with regards to acceptability of treatment and the level of compliance. Revisions were also made to previous recommendations in which testing included an evaluation of risk behaviours and need for consents. The newly revised guideline of United States Preventive Service Task Force [USPSTF] now advocates routine testing for all ages 18-65 years. All current treatment guidelines are now revised especially those by Department of Health and Human Services [USA],World Health Organisation [WHO],International AIDS Society ,all now recommends treatment for all infected with HIV virus irrespective of stage or duration. There is no more need to stage prior to commencement of treatment. It is hoped that the above two steps, screen all, treat all will help further in curtailing new infections as zero virus in the blood translates to zero new infections in the community. In March 2013, a case of possible cure was presented at the 2013 Conference on Retroviruses and Opportunistic infections in Atlanta by Dr Deborah Persaud, a virologist from Johns Hopkin hospital. She presented an infant from rural area of Mississippi who was delivered by a mother with HIV infection who never had any antenatal care. The child was started on multiple drug treatment 30 hours after birth considering her high risk with combination therapy. Blood tests on 3 occasions demonstrated HIV in the blood. He was on treatment for 12 months but was lost to follow up. During this time, the mother did not give any treatment. When the child was seen 12 months later, there were no more virus found. The implication of this finding is not yet conclusive but offers a hope of cure for infected new born infants. Prior to this accidental discovery, Timothy Ray Brown, a Berlin patient with leukemia had bone marrow transplant in 2007 from a donor with rare genetic mutation that can resist HIV infection while he continued anti-retroviral treatment. He was subsequently declared cured of HIV. Vaccine trial's have not recorded same level of success but the future is very bright. The need of HIV infected patients includes very good medical care, social support, family support and housing. The needs are mostly met with governmental financing, support from non profit organisations as well as privately funded foundations. Olayinka A. Adedayo MD,FACP The writer is a Diplomate of the American Board of Internal Medicine and a Member, New York Academy of Science.



Leave a Comment

Source: Caymannetnews

September 20th, 2013 - ubiquiti-networks-receives-new-coverage-from-analysts-at-credit-suisse-ubnt/#respond">0 comments - Filed Under - by Paige Hiatt

Credit Suisse began coverage on shares of Ubiquiti Networks (NASDAQ:UBNT) in a report released on Wednesday, reports. The firm issued a neutral rating and a $33.00 price objective on the stock.

"We believe that Ubiquiti has created a relatively unique business model that can disrupt several markets in the networking space over time. However, we believe shares are fully valued, with strong near-term revenue momentum offset by medium-term competitive risks and possible margin pressure. In the near term, we see possible upside to our revenue projections of $501mn for FY14 and $610mn for FY15, which are above consensus expectations. First, airMAX (65% of revenues) could see a continued rebound, given pent-up demand and the large opportunity in the WISP market. Second, UniFi is gaining traction in the WLAN segment. While the company's ambition to be number one in unit terms may appear lofty, achieving this could add a further $180mn in revenues, or 30% to our estimates for FY15.," the firm's analyst commented.

A number of other firms have also recently commented on UBNT. Analysts at Wunderlich raised their price target on shares of Ubiquiti Networks (NASDAQ:UBNT) from $33.00 to $40.00 in a research note to investors on Monday, August 26th. They now have a buy rating on the stock. Separately, analysts at Craig Hallum initiated coverage on shares of Ubiquiti Networks (NASDAQ:UBNT) in a research note to investors on Wednesday, August 21st. They set a buy rating on the stock. Finally, analysts at Zacks upgraded shares of Ubiquiti Networks (NASDAQ:UBNT) from a neutral rating to an outperform rating in a research note to investors on Tuesday, August 13th. They now have a $28.40 price target on the stock.

Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Ubiquiti Networks currently has an average rating of Buy and an average target price of $29.95.

Shares of Ubiquiti Networks ( NASDAQ:UBNT) traded down 4.23% during mid-day trading on Wednesday, hitting $31.22. The stock had a trading volume of 333,973 shares. Ubiquiti Networks has a 1-year low of $9.97 and a 1-year high of $37.40. The stock's 50-day moving average is $29.9 and its 200-day moving average is $19.96. The company has a market cap of $2.721 billion and a P/E ratio of 36.63.

In other Ubiquiti Networks news, major shareholder Peter Chung unloaded 13,000,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $33.00, for a total value of $429,000,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Ubiquiti Networks, Inc ( NASDAQ:UBNT) is a communications technology Company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Source: Northforkvue